Q-omics provides the consensus-scored CLDN14 profile across patient tissues and cancer cell-line models. CLDN14 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CLDN14 is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, CLDN14 RNA expression shows 12,439 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, HNSC, and TGCT as cancer lineages where CLDN14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLDN14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLDN14 survival associations across molecular data types. CLDN14 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLDN14 RNA expression–survival associations across cancer types. High CLDN14 expression shows unfavorable associations in MESO, KIRC, THCA, LGG and SCLC, but favorable associations in LIHC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CLDN14 RNA expression.
This table summarizes CLDN14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CLDN14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLDN14 shows lower tumor expression in KICH, KIRC and KIRP and higher tumor expression in HNSC, COAD and BLCA. The HNSC box plot shows higher CLDN14 RNA expression in tumor versus normal tissue (log2 FC = +1.112, t-test p < 0.001).
This table shows molecular features associated with CLDN14 in patient tissues and cancer cell lines. In patient samples, CLDN14 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CLDN14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Lymphoma.
